AnHeart Therapeutics Appoints Charlotte Arnold as Chief Corporate Affairs Officer

NEW YORK–()–AnHeart Therapeutics (“AnHeart”), a global clinical-stage biopharmaceutical company developing novel precision therapies for people with cancer, today announced the appointment of Charlotte Arnold as Chief Corporate Affairs Officer.

With more than 25 years of experience developing and executing corporate strategy for healthcare companies, Charlotte has joined AnHeart’s executive leadership team and will lead communications and investor relations for the company.

Charlotte is a highly regarded corporate affairs executive with extensive background in oncology, who has built and led multiple corporate affairs functions at both private and public biotech companies,” said Jerry Wang, PhD, Chief Executive Officer. “We are excited to welcome Charlotte to AnHeart’s leadership team as we continue to advance towards commercialization.”

Prior to joining AnHeart, Charlotte served as Senior Vice President, Corporate Affairs at Gyroscope Therapeutics, a global clinical-stage gene therapy company focused on eye disease, acquired by Novartis. She also served as Vice President, Corporate Affairs at GRAIL, Inc., acquired by Illumina, and Vice President, Corporate Communications and Investor Relations at Relypsa, Inc., acquired by Vifor Pharma. Previously, Charlotte held several senior communications roles at Genentech over the span of almost 10 years.

I’m very excited about AnHeart’s investigational therapies, which have the potential to make a real impact for people facing certain incurable cancers,” said Charlotte Arnold, Chief Corporate Affairs Officer. “I look forward to working with the AnHeart team to bring these potential therapies to patients who need new options.”

About AnHeart Therapeutics

AnHeart Therapeutics (“AnHeart”) is a global clinical-stage biopharmaceutical company developing novel precision therapies for people with cancer. Our lead investigational therapy, taletrectinib, is a next-generation ROS1-inhibitor currently in pivotal Phase 2 trials for ROS1-positive non-small cell lung cancer (NSCLC). Taletrectinib has been granted Breakthrough Therapy Designation by both the U.S. Food and Drug Administration and the China National Medical Products Administration. AnHeart’s second investigational therapy, safusidenib, is a mIDH1-inhibitor being evaluated in a Phase 2 trial for IDH1-mutant glioma.

Our mission is to improve the lives of people with cancer. We are supported by leading life sciences investors and have built an organization with deep oncology drug discovery and development expertise, with offices in New York and Shanghai. For more information, visit or follow us on LinkedIn at


Recent Articles